ASLAN Pharmaceuticals’ Varlitinib Selected by Leading Korean Gastric Cancer Group for Study in Second-Line Gastric Cancer

    NEXT STORY
    Global Companion Diagnostics Market to Witness a CAGR of 19% During 2019-2025
    PREV STORY
    Esoteric Testing Market revenue to hit $39 Billion by 2025: Global Market Insights, Inc.
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial

    author_avatar
    NASDAQ Market News

    Targovax ASA – Information on the subsequent offering – Key date information

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, ...

    author_avatar
    NASDAQ Market News

    RedHill Biopharma to Present New Phase 3 Data on RHB-105 and RHB-104 at the American College of Gastroenterology 2019 Annual Meeting

    author_avatar
    NASDAQ Market News